Our interest was so stimulated by the preliminary report of Maynard, entitled "Psoriasis Treated by Riboflavin,"1 that we undertook appraisal of the therapeutic effect of riboflavin in the treatment of psoriasis. Since Maynard's first report, we have studied with interest the positive and negative reports by Maynard, and by others. We summarize those reports briefly.
Clinical Experience of Others
Maynard's original study was based on response of 148 patients, 37 of whom were "healed"; 76 showed marked improvement (80% or better); 25 showed improvement (50% or more); 4 showed slight improvement (less than 50%); 6 failed to respond, and none worsened. "All these cases were given injections of riboflavin (5-10 mg. intramuscularly, usually once weekly) as a basic treatment. It has also been given orally in daily dosage coincident with the injections. In all cases local treatment has been dispensed with until proof of the patient's response
WELSH AL, EDE M. An Appraisal of the Therapeutic Effect of Riboflavin in Psoriasis. AMA Arch Derm. 1957;76(5):595–600. doi:10.1001/archderm.1957.01550230061010
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: